Skip to main content
. 2022 Apr 28;9(5):638. doi: 10.3390/children9050638

Table 2.

Different characteristics between Kawasaki disease (KD) and COVID-19.

Kawasaki Disease (KD) COVID-19
Etiology Unknown (coronavirus may be one of the triggers of KD) Human corona virus
Symptoms 5 major symptoms (fissure lips and/or strawberry tongue, bilateral non-purulent conjunctivitis, neck lymphadenopathy, limb induration, and polymorphic skin rash) Upper respiratory tract symptoms (non-specific or even asymptomatic)
Fever (>38 °C) 100% 60–70%
Treatment IVIG + aspirin (steroid for high-risk group) Anti-IL6, hydroxychloroquine, remdesivir, monoclonal antibodies, baricitinib, steroids, etc.
Age 85% < 5 years old 2% < 19 years old
Gender Male > female, 1.5-fold Male = female
BCG vaccine Scar induration May play a protective role
Abdominal pain 35% [19] 68% in MIS-C [20]
21% in COVID-19
Prevalence Asia > Americas > Europe Europe, Americas > Asia

°C: centigrade (body temperature); IVIG: intravenous immunoglobulin; IL6: interleukin 6; BCG: Bacillus Calmette–Guérin; MIS-C: multisystem inflammatory syndrome in children. Five major symptoms (1–2–3–4–5) of Kawasaki disease: 1 mouth (fissure lips and/or strawberry tongue), 2 eyes (bilateral non-purulent conjunctivitis), 3 fingers to check neck lymph node enlargement (neck lymphadenopathy), 4 limbs (induration or desquamation), and 5 days of fever with a polymorphic skin rash.